Global Custom Market Research Reports Provider Company

phone

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review

  • Published Date: 11 Apr 2018
  • Number of Pages: 49
  • Category: Pharmaceuticals
  • Country: United States of America
Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The companys marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc Key Recent Developments

Mar 13,2018: VIVUS Reports Fourth Quarter 2017 Financial Results
Dec 26,2017: VIVUS Announces Change in Leadership
Nov 07,2017: VIVUS Reports Third Quarter 2017 Financial Results
Aug 03,2017: VIVUS Reports Second Quarter 2017 Financial Results
May 24,2017: Thomas B. King Joins VIVUS Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Vivus Inc - Key Facts 5
Vivus Inc - Key Employees 6
Vivus Inc - Key Employee Biographies 7
Vivus Inc - Major Products and Services 9
Vivus Inc - History 10
Vivus Inc - Company Statement 14
Vivus Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 Company Analysis 18
Company Overview 18
Vivus Inc - Business Description 18
Vivus Inc - SWOT Analysis 19
SWOT Analysis - Overview 19
Vivus Inc - Strengths 19
Vivus Inc - Weaknesses 20
Vivus Inc - Opportunities 21
Vivus Inc - Threats 22
Vivus Inc - Key Competitors 23
Section 3 Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 Companys Lifesciences Financial Deals and Alliances 31
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Vivus Inc, Recent Deals Summary 33
Section 5 Companys Recent Developments 34
Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 34
Dec 26, 2017: VIVUS Announces Change in Leadership 36
Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 37
Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 39
May 24, 2017: Thomas B. King Joins VIVUS Board of Directors 41
May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 42
Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 43
Section 6 Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables

List of Tables
Vivus Inc, Key Facts 5
Vivus Inc, Key Employees 6
Vivus Inc, Key Employee Biographies 7
Vivus Inc, Major Products and Services 9
Vivus Inc, History 10
Vivus Inc, Subsidiaries 17
Vivus Inc, Key Competitors 23
Vivus Inc, Ratios based on current share price 24
Vivus Inc, Annual Ratios 25
Vivus Inc, Annual Ratios (Cont...1) 26
Vivus Inc, Annual Ratios (Cont...2) 27
Vivus Inc, Interim Ratios 29
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Vivus Inc, Recent Deals Summary 33
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48

List Of Figures

List of Figures
Vivus Inc, Performance Chart (2013 - 2017) 28
Vivus Inc, Ratio Charts 30
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The companys marketed products include,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports